Cerus (CERS) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cerus | 549.42 Mn | 469.73 Mn | 27.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.63% |
| Dec 31, 2025 | 25.23% |
| Sep 30, 2025 | 73.08% |
| Jun 30, 2025 | 17.41% |
| Mar 31, 2025 | 14.06% |
| Dec 31, 2024 | 29.48% |
| Sep 30, 2024 | 30.40% |
| Jun 30, 2024 | 19.94% |
| Mar 31, 2024 | 12.41% |
| Dec 31, 2023 | -2.49% |
| Sep 30, 2023 | 12.48% |
| Jun 30, 2023 | -0.07% |
| Mar 31, 2023 | -2.41% |
| Dec 31, 2022 | -9.81% |
| Sep 30, 2022 | 8.68% |
| Jun 30, 2022 | 13.25% |
| Mar 31, 2022 | 7.96% |
| Dec 31, 2021 | 39.36% |
| Sep 30, 2021 | 2.86% |
| Jun 30, 2021 | 3.30% |
| Mar 31, 2021 | -0.69% |
| Dec 31, 2020 | 4.99% |
| Sep 30, 2020 | 2.05% |
| Jun 30, 2020 | 1.42% |
| Mar 31, 2020 | -11.72% |
| Dec 31, 2019 | -24.19% |
| Sep 30, 2019 | -10.80% |
| Jun 30, 2019 | -18.27% |
| Mar 31, 2019 | -142.30% |
| Dec 31, 2018 | 55.67% |
| Sep 30, 2018 | 7.09% |
| Jun 30, 2018 | -14.58% |
| Mar 31, 2018 | -6.25% |
| Dec 31, 2017 | -39.32% |
| Sep 30, 2017 | -25.37% |
| Jun 30, 2017 | -25.07% |
| Mar 31, 2017 | -16.05% |
| Dec 31, 2016 | -12.62% |
| Sep 30, 2016 | -52.92% |
| Jun 30, 2016 | -23.17% |
| Mar 31, 2016 | -27.03% |
| Dec 31, 2015 | -40.18% |
| Sep 30, 2015 | -33.28% |
| Jun 30, 2015 | -32.53% |